溶血尿毒综合征 中国就医指南

Hemolytic Uremic Syndrome (HUS) is a rare, life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It primarily affects the microvasculature—especially in the kidneys—leading to endothelial damage, platelet activation, and fibrin deposition in small arterioles and capillaries. Pathogenesis varies by subtype: Shiga toxin–producing Escherichia coli (STEC-HUS), most commonly linked to E. coli O157:H7 infection following ingestion of undercooked beef or contaminated produce, triggers endothelial injury via ribosomal inactivation and proinflammatory cytokine release. Atypical HUS (aHUS), accounting for ~5–10% of cases, is driven by uncontrolled complement system activation due to genetic mutations (e.g., in CFH, CFI, MCP, C3, or THBD) or autoantibodies against complement regulatory proteins. A third category—secondary HUS—may arise from infections (e.g., pneumococcus), malignancies, autoimmune disorders (e.g., SLE), pregnancy, or certain medications (e.g., calcineurin inhibitors, chemotherapy). Epidemiologically, STEC-HUS peaks in children under 5 years, with an incidence of ~2–3 cases per 100,000 children annually in high-income countries; aHUS has an estimated incidence of 0.2–0.3 per million per year and affects all ages, with median onset in adulthood. Risk factors include young age (for STEC-HUS), inherited complement dysregulation (for aHUS), immunosuppression, recent gastrointestinal illness, and underlying conditions such as hypertension or chronic kidney disease. HUS imposes profound quality-of-life impacts: acute phase symptoms—including pallor, fatigue, oliguria/anuria, edema, seizures, and altered mental status—can necessitate ICU admission, dialysis, and prolonged hospitalization. Survivors often face long-term sequelae: 25–50% develop chronic kidney disease, 3–5% progress to end-stage renal disease requiring transplantation, and neurocognitive deficits, hypertension, and cardiovascular complications may persist. Psychosocial burden includes anxiety, depression, school or work disruption, caregiver strain, and financial hardship—particularly where access to plasma exchange, eculizumab, or specialized nephrology-hematology care is limited. Early recognition and multidisciplinary management involving hematologists, nephrologists, intensivists, and pediatric specialists are critical to mitigating morbidity and mortality.

# 溶血尿毒综合征（HUS）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：典型感染相关HUS（如大肠埃希菌O157:H7）、轻中度溶血、eGFR >30 mL/min/1.73m²、无严重神经系统受累。

• •支持治疗：水化、电解质管理、红细胞输注（限Hb <70 g/L）、血小板输注（仅活动性出血或侵入性操作前）

• •血浆置换（PEX）：每日1次，持续5–7日，用于非典型HUS（aHUS）或重症典型HUS

- 单次PEX费用：2,800–4,500元；全程5次合计 14,000–22,500元

二、靶向药物治疗（核心方案）

适用人群：aHUS确诊、补体旁路异常激活、复发或PEX依赖者。

• •依库珠单抗（C5抑制剂）：首周2次负荷剂量+后续每14天维持

• •泊洛妥珠单抗（新型C5抑制剂）：2024年纳入医保，年自付约180,000–220,000元

三、特殊复杂情况处理

• •终末期肾病合并HUS：需长期透析+依库珠单抗，年综合费用350,000–520,000元
• •移植后复发aHUS：联合依库珠单抗+免疫抑制调整，首年费用480,000–650,000元

四、方案快速选择指南

• •预算有限（<5万元）：首选支持治疗+PEX（限典型HUS）
• •确诊aHUS/复发风险高：立即启动依库珠单抗（医保报销后优选）
• •儿童初发典型HUS：支持治疗为主，避免过早PEX/靶向药（自限性率>85%）